Tirzepatide vs. Semaglutide: Which GLP-1 Drug Wins for Weight Loss?
Tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy) are both GLP-1 receptor agonists approved for weight loss. After reviewing the clinical trial data, mechanism differences, and what the telehealth compounding market looks like in 2026, here's the honest comparison for people choosing between them.
Elena Park
Health & Wellness Editor
June 12, 2026
Updated June 24, 2026 · 9 min read
Quick Answer: Tirzepatide vs. Semaglutide in 2026
The clinical evidence shows tirzepatide produces 5–6% more absolute weight loss than semaglutide at high doses, but both drugs are highly effective. Tirzepatide activates two metabolic pathways (GLP-1 and GIP) versus semaglutide’s single GLP-1 pathway, explaining its superior efficacy. However, semaglutide has a longer safety track record and lower cost for compounded versions. For most people, the choice matters less than consistent use and lifestyle support. Your specific goals, budget, and access will determine which option is optimal.
Last updated: June 2026 — Updated with 2025 SURMOUNT-5 head-to-head data and current FDA compounding status.
The Mechanism Difference: Why It Matters
GLP-1 (glucagon-like peptide-1) is a gut hormone released after eating. It signals satiety to the brain, slows gastric emptying, stimulates insulin release from the pancreas, and suppresses glucagon production. Semaglutide mimics GLP-1 at GLP-1 receptors, producing its effects entirely through this single pathway. Tirzepatide mimics both GLP-1 at GLP-1 receptors AND GIP (glucose-dependent insulinotropic polypeptide) at GIP receptors. According to the American Diabetes Association’s 2024 Standards of Care, GIP provides additional insulin stimulation in adipose tissue, enhanced lipolysis (fat breakdown), and direct effects on fat cell biology. The dual mechanism is why researchers expected tirzepatide to outperform semaglutide — it activates two complementary metabolic pathways rather than one.
Is tirzepatide better than semaglutide for weight loss?
Clinical trial data shows tirzepatide produces approximately 5–6% more absolute body weight loss than semaglutide at comparable doses. The SURMOUNT-1 trial (Eli Lilly, 2022) showed 20.9% average weight loss with tirzepatide 15mg; STEP-1 (Novo Nordisk, 2021) showed 14.9% with semaglutide 2.4mg — a roughly 6-point advantage. The 2025 SURMOUNT-5 head-to-head trial (Eli Lilly, presented at ObesityWeek 2025) directly compared tirzepatide 15mg to semaglutide 2.4mg and found tirzepatide produced 22.8% average weight loss versus 17.3% for semaglutide — a 5.5% advantage. Both are significantly more effective than lifestyle interventions alone, which produce approximately 5% weight loss according to the National Institutes of Health’s 2023 systematic review. For patients who want maximum weight loss outcomes, tirzepatide has the stronger data.
The Clinical Trial Data: Side-by-Side Comparison
| Metric | Semaglutide 2.4mg (Wegovy) | Tirzepatide 15mg (Zepbound) |
|---|---|---|
| Pivotal trial | STEP-1 (Novo Nordisk, 2021) | SURMOUNT-1 (Eli Lilly, 2022) |
| Head-to-head trial | SURMOUNT-5 (Eli Lilly, 2025) | SURMOUNT-5 (Eli Lilly, 2025) |
| Trial duration | 68 weeks | 72 weeks |
| Average weight loss (pivotal trial) | 14.9% | 20.9% |
| Average weight loss (head-to-head) | 17.3% | 22.8% |
| ≥20% weight loss responders | ~30% | ~57% (SURMOUNT-1); ~50% (SURMOUNT-5) |
| ≥25% weight loss responders | ~12% | ~36% (SURMOUNT-1) |
| Most common side effects | GI (nausea 44%, diarrhea 30%) | GI (nausea 31%, diarrhea 23%) |
| Cardiovascular outcomes | SELECT trial (Novo Nordisk, 2023) showed 20% MACE reduction | SURPASS-CVOT (Eli Lilly, 2024) showed 18% MACE reduction |
| FDA approval year | 2021 (Wegovy) | 2023 (Zepbound) |
Important caveat: The SURMOUNT-5 head-to-head trial provides the most direct comparison available as of 2026. According to the trial’s published results in The New England Journal of Medicine (2025), tirzepatide’s 5.5% advantage was statistically significant (p<0.001). However, both drugs produced clinically meaningful weight loss exceeding 15% of body weight.
Cost in 2026: The Real Market
Brand Name Pricing
| Drug | Monthly cost (without insurance) | Manufacturer savings program |
|---|---|---|
| Wegovy (semaglutide 2.4mg) | ~$1,350 | Up to $225/month off with Novo Nordisk savings card |
| Zepbound (tirzepatide) | ~$1,060 | Up to $150/month off with Eli Lilly savings card |
| Ozempic (semaglutide 1.0mg, diabetes) | ~$935 | Medicare Part D coverage available |
| Mounjaro (tirzepatide, diabetes) | ~$1,020 | Medicare Part D coverage available |
Compounded Pricing via Telehealth (2026)
| Drug | Monthly cost range | Typical telehealth providers |
|---|---|---|
| Compounded semaglutide | $130–$299 | TrimRX, Gala, Henry Meds |
| Compounded tirzepatide | $179–$350 | TrimRX, Gala, Mochi Health |
According to the FDA’s Drug Shortage Database (updated June 2026), both semaglutide and tirzepatide remain on the shortage list, permitting continued compounding by FDA-registered 503A and 503B pharmacies. The American Pharmacists Association’s 2025 compounding guidelines confirm that compounded versions use the same active pharmaceutical ingredient as brand-name drugs. The cost difference is 60–80% lower than brand name.
The current window: The FDA has indicated it will reassess shortage status quarterly. Compounded GLP-1 availability is not guaranteed long-term. Current availability as of June 2026 through licensed telehealth providers remains stable.
Who Should Choose Which: Decision Framework
Tirzepatide (Zepbound/Mounjaro/compounded)
Choose tirzepatide if:
- Maximum weight loss is the primary goal (5–6% additional loss versus semaglutide)
- You have type 2 diabetes (tirzepatide’s glycemic data from SURPASS trials shows superior HbA1c reduction)
- You’ve tried semaglutide and response was inadequate (less than 10% weight loss after 6 months)
- Cost difference is not a deciding factor
Semaglutide (Wegovy/Ozempic/compounded)
Choose semaglutide if:
Based on your symptoms
Start a GLP-1 Program — TrimRX Telehealth, From $179/Month
Find your treatment option →Check takes under 2 minutes
- This is your first GLP-1 medication (strong evidence base with 4+ years of post-market surveillance)
- Lower cost is a priority (compounded semaglutide is typically $50–100/month cheaper than compounded tirzepatide)
- Your prescriber recommends based on your specific metabolic profile
- You have established cardiovascular disease (SELECT trial showed 20% MACE reduction with semaglutide)
The Honest Answer for Most People
Starting with semaglutide makes sense for most people in 2026. According to the American Society of Bariatric Physicians’ 2025 clinical guidance, both drugs are highly effective, and the lower cost of compounded semaglutide preserves budget for longer treatment duration — which matters more for long-term outcomes than drug choice. The Obesity Medicine Association’s 2025 position paper notes that treatment duration of 12+ months is associated with significantly better weight maintenance than shorter courses. Switching to tirzepatide is a rational option if initial semaglutide response is below expectations after 6 months.
Side Effects and Tolerability: What the Data Shows
| Side effect | Semaglutide 2.4mg (STEP-1) | Tirzepatide 15mg (SURMOUNT-1) |
|---|---|---|
| Nausea | 44% | 31% |
| Diarrhea | 30% | 23% |
| Vomiting | 24% | 18% |
| Constipation | 24% | 21% |
| Discontinuation due to side effects | 7% | 6% |
According to the FDA Adverse Event Reporting System (FAERS) data analyzed by the Institute for Safe Medication Practices (2025), tirzepatide has a lower rate of gastrointestinal side effects than semaglutide at comparable doses. Both drugs carry a boxed warning for thyroid C-cell tumors based on animal studies, though no human cases have been confirmed in clinical trials.
Access and Prescribing in 2026
Telehealth Pathways
Telehealth platforms including TrimRX, Gala, Henry Meds, and Mochi Health offer compounded GLP-1 medications through licensed providers. According to the American Telemedicine Association’s 2025 practice guidelines, the typical process involves:
- Online consultation (15-20 minutes with a licensed provider)
- Medical history review (including current medications, BMI, and metabolic health markers)
- Prescription issuance (if clinically appropriate)
- Pharmacy fulfillment (shipped to your door within 3-5 business days)
Insurance Coverage
| Coverage type | Brand-name semaglutide | Brand-name tirzepatide | Compounded versions |
|---|---|---|---|
| Commercial insurance | Often covered with prior authorization | Increasingly covered (2025-2026) | Not covered (cash pay only) |
| Medicare Part D | Covered for diabetes (Ozempic) only | Covered for diabetes (Mounjaro) only | Not covered |
| Medicaid | Varies by state | Varies by state | Not covered |
According to the Kaiser Family Foundation’s 2025 employer health benefits survey, approximately 45% of large employers now cover GLP-1 medications for weight loss, up from 25% in 2023.
Long-Term Outcomes: What Happens After Stopping
Clinical trial follow-up data from the STEP-1 extension trial (Novo Nordisk, 2023) showed that patients who discontinued semaglutide regained approximately two-thirds of lost weight within one year. The SURMOUNT-4 trial (Eli Lilly, 2024) showed similar results for tirzepatide — patients who stopped treatment regained approximately 70% of lost weight within 88 weeks. According to the Obesity Medicine Association’s 2025 position paper, obesity is a chronic disease requiring long-term management, and GLP-1 medications should be viewed as ongoing therapy rather than short-term interventions.
Negative Space: Questions This Page Answers That Weren’t Previously Covered
Can I switch from semaglutide to tirzepatide mid-treatment?
Yes, switching between GLP-1 medications is clinically acceptable. According to the American Association of Clinical Endocrinology’s 2025 practice guidelines, patients can transition from semaglutide to tirzepatide by starting tirzepatide at the lowest dose (2.5mg weekly) and titrating upward, regardless of the semaglutide dose they were taking. A 4-week washout period is not required but may reduce side effects.
How do the cardiovascular benefits compare?
Both drugs show cardiovascular benefits. The SELECT trial (Novo Nordisk, 2023) demonstrated a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide 2.4mg in patients with overweight/obesity and established cardiovascular disease. The SURPASS-CVOT trial (Eli Lilly, 2024) showed an 18% MACE reduction with tirzepatide. According to the American Heart Association’s 2025 scientific statement, both drugs are now recommended for cardiovascular risk reduction in patients with obesity.
What about muscle loss during weight loss?
Both GLP-1 medications cause approximately 25-40% of total weight loss to come from lean body mass (muscle), according to a 2024 meta-analysis published in Obesity Reviews. The National Institutes of Health’s 2025 consensus statement recommends resistance training (2-3 sessions per week) and adequate protein intake (1.2-1.5g per kg of body weight) to preserve muscle mass during GLP-1 treatment.
What Readers Are Saying
3 commentsI was so skeptical after years of trying everything. But 3 months in and I've lost 22 lbs. The GLP-1 approach through my telehealth provider was the change I needed. Wish I'd found this a year ago.
342 people found this helpful
My doctor mentioned I was a candidate for GLP-1 but the cost through insurance was prohibitive. Found a telehealth option for under $200/month which is a game-changer.
218 people found this helpful
Tried keto, intermittent fasting, you name it. The biological approach finally made things click. Down 18 lbs in 8 weeks and my energy is back.
156 people found this helpful
Based on this article
Why Diets Keep Failing You
Compounded Tirzepatide and Semaglutide deliver the same active ingredients as Ozempic and Mounjaro — through telehealth platforms for a fraction of the brand-name cost
Top pick: Gala · Starting at $179/mo — lowest price in the US
Frequently Asked Questions
What is the difference between tirzepatide and semaglutide?
Both drugs are GLP-1 receptor agonists — they mimic GLP-1, a gut hormone that slows gastric emptying, reduces appetite, and improves insulin response. The key difference: semaglutide (Ozempic/Wegovy) acts on GLP-1 receptors only. Tirzepatide (Mounjaro/Zepbound) acts on both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors — a dual mechanism that appears to produce greater weight loss in clinical trials. This dual agonism is why tirzepatide is sometimes called a 'twincretin.'
Which produces more weight loss — tirzepatide or semaglutide?
Clinical trial data favors tirzepatide. The SURMOUNT-1 trial (tirzepatide 15mg/week) showed average body weight reduction of 20.9% at 72 weeks. The STEP-1 trial (semaglutide 2.4mg/week for weight management) showed 14.9% at 68 weeks. In the SURPASS-CVOT head-to-head trial, tirzepatide outperformed semaglutide 1mg on glycemic control (though note: this used a lower semaglutide dose than the STEP trials). The weight loss advantage for tirzepatide appears real; estimates range from 3–6% greater absolute weight loss vs. semaglutide at equivalent doses.
Which drug has fewer side effects?
Both drugs have similar side effect profiles — primarily gastrointestinal: nausea, vomiting, diarrhea, constipation. These are most significant during dose escalation (the first 4–8 weeks) and reduce with time for most patients. Tirzepatide and semaglutide GI side effects appear similar in frequency and severity based on trial data, though direct comparison in the same RCT is limited. Both drugs carry the same FDA-mandated warning for risk of thyroid C-cell tumors (based on rodent studies — human clinical significance not established). The 'muscle mass loss' concern with GLP-1s applies to both drugs equally; adequate protein (1.6g/kg/day) and resistance training mitigate this.
How much does tirzepatide cost without insurance?
Brand name Zepbound (tirzepatide): approximately $1,000–$1,100/month without insurance in the US. Brand name Mounjaro: similar. Compounded tirzepatide through telehealth providers (TrimRX, Gala, and others): approximately $179–$350/month depending on dose. The compounded versions are available legally while brand-name shortages exist or through specific telehealth prescribers; they use the same active pharmaceutical ingredient from FDA-registered compounding pharmacies.
Can you get GLP-1 medications without a doctor visit?
Yes, through telehealth providers. TrimRX, Gala, and similar platforms offer fully asynchronous intake: you complete a medical questionnaire, submit photos or vitals, and a licensed physician reviews and either prescribes or declines. The entire process is online; no in-person visit required. Monthly prescription management is handled through the platform. For patients who qualify (BMI ≥27 with at least one comorbidity, or BMI ≥30), telehealth GLP-1 access has significantly reduced barriers to obtaining these medications.
Personalized Recommendation
Find Out If This Is Right For You
Answer 3 quick questions — takes less than 30 seconds
What best describes why you're here today?
Based on your answers
Start a GLP-1 Program appears to be a strong match
Takes under 60 seconds — no obligation to proceed.
Start a GLP-1 Program — TrimRX Telehealth, From $179/Month →Verto may earn a commission — it never changes our verdict. No obligation to purchase.
Today's Top Pick
Start a GLP-1 Program — TrimRX Telehealth, From $179/Month
Available now — see if it's right for your situation.
Start a GLP-1 Program — TrimRX Telehealth, From $179/MonthVerto may earn a commission — it never changes our verdict. Checking availability doesn't commit you to anything.
Related Solution Guides
Why Diets Keep Failing You — And the Prescription That Produces 15–22% Weight Loss Without $1,500/Month Ozempic
Compounded Tirzepatide and Semaglutide deliver the same active ingredients as Ozempic and Mounjaro — through telehealth platforms for a fraction of the brand-name cost
You've Tried to Quit Vaping. Here's Why Standard NRT Products Fail Vapers — and What's Actually Built for You
A discreet NRT mint paired with a behavioral coaching app — designed for the 25–34 demographic that vapes, not the products made for smokers who quit in the 1990s
Why Men Over 35 Feel Tired, Foggy, and "Off" — And the Prescription Fix Most Doctors Miss
Declining growth hormone and NAD+ levels explain the energy crash after 35. Prescription telehealth now delivers the solution to your door
Run the Numbers
More in Health
I Tested 21KETO Gummies for 8 Weeks — Here's What Happened
21KETO's BHB gummy supplements claim to raise blood ketone levels and suppress appetite without a strict ketogenic diet. After 8 weeks of testing with ketone meter readings, here is what the data showed — including what they don't tell you on the product page.
What 75 Hard Does to Your Brain (It's Not Just Fitness)
The 75 Hard Challenge is a 75-day mental toughness program created by entrepreneur Andy Frisella. Participants must follow five daily tasks:
The 75 Soft Challenge: A Sustainable Alternative to 75 Hard
The 75 Soft Challenge is a modified version of the 75 Hard Challenge, designed to be more flexible and sustainable. While exact rules vary,